New Binding Efficacy and Mode of Action Assays for Rituximab
July 26, 2011 - Charles River offers a wide variety of optimized, fully GMP-compliant bioassays. As part of our vast portfolio of products and services, we now offer two new bioassays for Rituximab–an approved chimeric monoclonal antibody for the treatment of cancer.
Binding Assay for Rituximab
This flow cytometry-based binding assay measures the binding efficacy of Rituximab to CD20-expressing Ramos human lymphoma cells. In this test, Rituximab is titrated on these cells and a fluorescently labeled antihuman secondary antibody is used to detect Rituximab’s dose-dependent binding. This Rituximab binding assay was validated according to ICH guideline Q2 (R1).
ADCC Mode of Action Assay for Rituximab
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) refers to a cell-mediated reaction. Target cells coated with a therapeutic antibody are killed by effector cells. In this mode of action assay, natural killer (NK) cells–derived from periphery blood mononuclear cells (PBMC) of healthy donors–are used as effector cells. NK cells recognize their target cells via the receptors for the Fc fragment of IgG (FcgRIIIA, CD16) that bind to antibody bound to the surface of the target cells. Binding of NK cells to target cells induces lysis of the target cells by direct cell-to-cell contact.
Expertise in Bioassay Development
Charles River has immense experience in the development of cell-based potency and mode of action assays for monoclonal antibodies (e.g., Trastuzumab, Bevacizumab and Infliximab) as well as assays for recombinant proteins (e.g., interferons, erythropoietins and various growth factors). All services are performed in full compliance with cGMP.
Both assays–binding and mode of action for Rituximab–will be presented at BEBPA's 4th Annual Bioassay Conference on September 28-30, 2011, in Nice, France. To learn more about either of these assays, please email us at email@example.com.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We can now analyze immunohistochemical biomarkers using a confocal microscope by having multiple images taken at relatively high magnification, thus allowing us the ability to construct an image of the brain section in good resolution.
Our newly validated ELISpot and FluoroSpot reader services are some of the most sensitive cellular assays available. With this technology, we now offer an even wider range of services to meet vaccine development needs.
Jun 24–Jun 26
Charles River is once again delighted to be supporting Skin Forum. Our expert scientists will be attending the Annual Meeting and will be happy to meet with you to discuss your dermal product requirements and help you determine how our global capabilities can benefit your development program.
Jun 21–Jun 25
This five-day meeting draws diverse professionals from around the world to share their breakthroughs in the prevention, diagnosis and treatment of diabetes.
Sep 09–Sep 11
This year's "Biotechnology-Derived Therapeutics: Perspectives on Nonclinical Development" Symposium will be held on September 9-11 at the Hilton Carlsbad Oceanfront Resort and Spa in Carlsbad, CA. This Charles River sponsored event unites drug development professionals in an interactive setting to discuss the nonclinical development of biologics, including regulatory issues and innovative approaches to problem-solving.
Jun 28–Jun 28
Charles River offers a wide range of seminars, workshops and training courses for animal technicians, veterinarians, biologists and laboratory technicians who work with laboratory animals. For more information about our course on animal health monitoring, click "view more" below.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.